PA5-54651

antibody from Invitrogen Antibodies

Targeting: RUFY3 KIAA0871, RIPx, Singar1, ZFYVE30

Western blot (Supportive data in Antibodypedia)

Immunocytochemistry (Supportive data in Antibodypedia)

Immunohistochemistry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-54651

Provider

Invitrogen Antibodies

Product name

RIPX Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Recombinant full-length protein

Description

Immunogen sequence: MLEKDVCEKQ DALVSLRQQL DDLRALKHEL AFKLQSSDLG VKQKSELNSR LEEKTNQMAA TIKQLEQRLR QAERSRQSAE LDNRLFKQDF GDKINSLQLE VEELTRQRNQ LEL

Concentration

0.2 mg/mL

References

Submitted references

Roles of Rufy3 in experimental subarachnoid hemorrhage-induced early brain injury via accelerating neuronal axon repair and synaptic plasticity.

Wang Y, Xu J, You W, Shen H, Li X, Yu Z, Li H, Chen G
Molecular brain 2022 Apr 23;15(1):35

Western blot

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis of RIPX in Lane 1: NIH-3T3 cell lysate (Mouse embryonic fibroblast cells); Lane 2: NBT-II cell lysate (Rat Wistar bladder tumour cells). Samples were probed using a RIPX Polyclonal Antibody (Product # PA5-54651).

Immunocytochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescent staining of RIPX in human cell line A-431 using a RIPX Polyclonal Antibody (Product # PA5-54651) shows localization to cytosol.

Immunohistochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunohistochemical staining of RIPX in human cerebral cortex using a RIPX Polyclonal Antibody (Product # PA5-54651) shows moderate cytoplasmic positivity in neuronal cells.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Rufy3 mRNA and protein expression levels and neuronal axon damage following SAH. a Quantitative analysis of Rufy3 mRNA level. The sham group was used as a control. b Representative band of Rufy3 detected by western blot. c Quantitative analysis of Rufy3 at different stages following SAH. The sham group was used as a control. d - f Double immunofluorescence of Rufy3, MBP, and N52 (green, Alexa Fluor 488) and neuronal marker (NeuN; red, Alexa Fluor 555), and Rufy3 mainly located in the neurons. Nuclei were stained with DAPI (blue). Scale bars = 100 mum. g - i Immunopositivity of Rufy3, MBP, and N52 in neurons. The Sham group was used as the standard. Data are shown as mean +- SEM ( n = 6). * P < 0.05, ** P < 0.01, *** P < 0.01, vs. Sham group

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

The protein expression levels of Rufy3 and the state of neuronal axon under LV-shRNA and LV-Rufy3 treatments after vivo and vitro SAH. a Representative bands of Rufy3 detected by western blot under 8p-CPT, LV-shRNA and LV-Rufy3 treatments following vivo SAH. b Representative bands of Rufy3 detected by western blot under LV-shRNA and LV-Rufy3 treatments following vitro SAH. c , d Quantitative analysis of Rufy3 in different groups following vivo and vitro SAH. The sham and control group were used as a control. e Double immunofluorescence analysis of Rufy3 (green, Alexa Fluor 488) and beta-tubulin III (NeuN; red, Alexa Fluor 555); nuclei were stained with DAPI (blue). Scale bars = 32 mum. f, g Quantitative fluorescent intensity analysis of Rufy3 and beta-tubulin III expressions in different groups. The sham group was used as the standard. h Quantitative analysis of the length of neuronal axon in different groups. i Double immunofluorescence of Rufy3 (green, Alexa Fluor 488) and beta-tubulin III (axon; red, Alexa Fluor 555). Nuclei were stained with DAPI (blue). Scale bars = 100 mum. Data are shown as mean +- SEM ( n = 6). ** P < 0.01, ** P < 0.001 vs. Sham group; * P < 0.001 vs. Control group; # P < 0.05, ## P < 0.01 vs. LV-NC1 groups; & P < 0.05, && P < 0.01, &&& P < 0.001 vs. LV-NC2 group; $ P < 0.05 vs. LV-Rufy3 group